| Medical and Health Sciences | 2021-2025 | 127 | US 53 | 99.98 |
| Surgery | Lifetime | 176 | US 97 | 99.85 |
| Endocrinology, Diabetes and Metabolism | Lifetime | 286 | US 159 | 99.13 |
| Cardiology and Cardiovascular Medicine | Lifetime | 672 | US 354 | 98.80 |
| Radiology, Nuclear Medicine and Imaging | Lifetime | 716 | US 396 | 98.13 |
| Pharmacology | Lifetime | 843 | US 333 | 85.11 |
| Surgery | 2021-2025 | 9 | US 4 | 99.96 |
| Endocrinology, Diabetes and Metabolism | 2021-2025 | 132 | US 62 | 97.98 |
| Cardiology and Cardiovascular Medicine | 2021-2025 | 254 | US 122 | 97.96 |
| Medical Physiology | 2021-2025 | 944 | US 346 | 83.87 |
| Cardiac Imaging and Diagnostics | Lifetime | 232 | US 125 | 99.59 |
| Lipoproteins and Cardiovascular Health | Lifetime | 103 | US 57 | 99.40 |
| Coronary Interventions and Diagnostics | Lifetime | 149 | US 73 | 99.49 |
| Diabetes Treatment and Management | Lifetime | 169 | US 76 | 99.28 |
| Acute Myocardial Infarction Research | Lifetime | 338 | US 166 | 98.90 |
| Pharmacology and Obesity Treatment | Lifetime | 160 | US 75 | 97.99 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | Lifetime | 478 | US 205 | 98.41 |
| Pharmaceutical Economics and Policy | Lifetime | 201 | US 109 | 97.11 |
| Metabolism, Diabetes, and Cancer | Lifetime | 596 | US 259 | 97.85 |
| Antiplatelet Therapy and Cardiovascular Diseases | Lifetime | 449 | US 181 | 97.97 |
| Bariatric Surgery and Outcomes | Lifetime | 271 | US 132 | 97.11 |
| Cancer, Lipids, and Metabolism | Lifetime | 883 | US 408 | 96.97 |
| Health and Medical Research Impacts | Lifetime | 334 | US 194 | 93.53 |
| Peroxisome Proliferator-Activated Receptors | Lifetime | 990 | US 417 | 94.66 |
| Pharmaceutical industry and healthcare | Lifetime | 555 | US 316 | 86.11 |
| Aortic Thrombus and Embolism | Lifetime | 236 | US 103 | 84.31 |
| Lipoproteins and Cardiovascular Health | 2021-2025 | 11 | US 3 | 99.77 |
| Cancer, Lipids, and Metabolism | 2021-2025 | 31 | US 11 | 99.14 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | 2021-2025 | 60 | US 21 | 97.87 |
| Cardiomyopathy and Myosin Studies | 2021-2025 | 158 | US 71 | 95.66 |
| Antiplatelet Therapy and Cardiovascular Diseases | 2021-2025 | 167 | US 37 | 96.24 |
| Bariatric Surgery and Outcomes | 2021-2025 | 142 | US 40 | 95.27 |
| Health Systems, Economic Evaluations, Quality of Life | 2021-2025 | 638 | US 212 | 94.81 |
| Fatty Acid Research and Health | 2021-2025 | 99 | US 32 | 92.51 |
| Pharmaceutical Economics and Policy | 2021-2025 | 106 | US 43 | 92.84 |
| Pharmacology and Obesity Treatment | 2021-2025 | 74 | US 37 | 93.46 |
| Diet and metabolism studies | 2021-2025 | 898 | US 268 | 92.58 |
| Hormonal and reproductive studies | 2021-2025 | 251 | US 65 | 89.92 |
| Eicosanoids and Hypertension Pharmacology | 2021-2025 | 112 | US 46 | 86.03 |
| Coronary Interventions and Diagnostics | 2021-2025 | 863 | US 179 | 91.23 |
| Lipid metabolism and disorders | 2021-2025 | 950 | US 181 | 59.29 |
